BTIG Downgrades Sigilon Therapeutics to Neutral
Portfolio Pulse from richadhand@benzinga.com
BTIG analyst Thomas Shrader has downgraded Sigilon Therapeutics (NASDAQ:SGTX) from Buy to Neutral.
June 30, 2023 | 8:50 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sigilon Therapeutics has been downgraded from Buy to Neutral by BTIG analyst Thomas Shrader.
The downgrade from Buy to Neutral by BTIG analyst Thomas Shrader indicates a less optimistic outlook for Sigilon Therapeutics. This could potentially lead to a decrease in the stock price in the short term as investors may interpret this as a signal to sell or hold off on buying the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100